Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
(Created page with "== Management == * Ceftolozane-tazobactam ** * Ceftazidime-avibactam ** Special Access Program * Fosfomycin ** * Colistin ** * Cefiderocol ** Special A...") |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | == |
+ | == Background == |
| + | * Defined by the European CDC<ref>Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. ''Clin Microbiol Infect''. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. PMID: 21793988.</ref> as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism |
||
| ⚫ | |||
| + | * Refer to to [[Multidrug-resistant organism|multidrug-resistant organisms]] for specific |
||
| − | ** |
||
| + | |||
| − | * [[Ceftazidime-avibactam]] |
||
| + | ==Management== |
||
| − | ** Special Access Program |
||
| + | |||
| ⚫ | |||
| ⚫ | |||
| − | ** |
||
| + | **May be better for multidrug-resistance [[Pseudomonas]] (or at least more experience with it) |
||
| ⚫ | |||
| + | *[[Ceftazidime-avibactam]]: available through Special Access Program |
||
| − | ** |
||
| + | **Adds coverage of some carbapenemases and AmpC |
||
| − | * [[Cefiderocol]] |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| − | * [[Meropenem-vaborbactam]] |
||
| ⚫ | |||
| − | * |
+ | *[[Meropenem-vaborbactam]]: still awaiting Health Canada Drug Review |
| − | * [[Imipenem-relebactam]] |
||
| − | * |
+ | *[[Imipenem-relebactam]] (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review |
| − | ** Awaiting Health Canada Drug Review |
||
Latest revision as of 17:18, 2 October 2022
Background
- Defined by the European CDC[1] as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism
- Refer to to multidrug-resistant organisms for specific
Management
- Ceftolozane-tazobactam (Zerbaxa)
- May be better for multidrug-resistance Pseudomonas (or at least more experience with it)
- Ceftazidime-avibactam: available through Special Access Program
- Adds coverage of some carbapenemases and AmpC
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
- ↑ Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. PMID: 21793988.
